Patents by Inventor Blaine Bueche

Blaine Bueche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190343768
    Abstract: A dry powder insulin formulation for reconstitution including insulin, a buffering agent, and a salt. The dry powder insulin formulation includes between about 70 and 95% w/w of insulin, between about 5 and 30% w/w of the buffering agent, and less than about 1% w/w of the salt. The dry powder insulin formulation has less than about 5% water content.
    Type: Application
    Filed: May 14, 2019
    Publication date: November 14, 2019
    Inventors: Blaine Bueche, Matthew Sander, Mei-chang Kuo
  • Publication number: 20190160153
    Abstract: Liquid formulations of insulin that contain physically and chemically stable insulin but do not contain preservatives or stabilizers are provided. The formulations also lack surfactants. The formulations are useful for various modes of delivery including pulmonary delivery.
    Type: Application
    Filed: October 23, 2018
    Publication date: May 30, 2019
    Applicant: Dance BioPharm, Inc.
    Inventors: Blaine Bueche, Mei-Chang Kuo, John Patton, Matthew Sander
  • Publication number: 20190054259
    Abstract: Liquid formulations of insulin that contain physically and chemically stable insulin but do not contain preservatives or stabilizers are provided. The formulations also lack surfactants. The formulations are useful for various modes of delivery including pulmonary delivery.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 21, 2019
    Applicant: Dance BioPharm, Inc.
    Inventors: Blaine Bueche, Mei-Chang Kuo, John Patton, Matthew Sander
  • Patent number: 9968603
    Abstract: Therapeutic agent delivery formulations for the sustained release of therapeutic agents from a Port Delivery System (PDS) implant is described in this application.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 15, 2018
    Assignee: FORSIGHT VISION4, INC.
    Inventors: Irina Astafieva, Judit Horvath, Kathleen Cogan Farinas, Blaine Bueche, Signe Erickson
  • Publication number: 20170258634
    Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
  • Publication number: 20160243199
    Abstract: Liquid formulations of insulin that contain physically and chemically stable insulin but do not contain preservatives or stabilizers are provided. The formulations also lack surfactants. The formulations are useful for various modes of delivery including pulmonary delivery.
    Type: Application
    Filed: December 21, 2015
    Publication date: August 25, 2016
    Applicant: Dance BioPharm, Inc.
    Inventors: Blaine Bueche, Mei-Chang Kuo, John Patton, Matthew Sander
  • Publication number: 20140276482
    Abstract: Therapeutic agent delivery formulations for the sustained release of therapeutic agents from a Port Delivery System (PDS) implant is described in this application.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Irina Astafieva, Judit Horvath, Kathleen Cogan Farinas, Blaine Bueche, Signe Erickson
  • Publication number: 20140031769
    Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.
    Type: Application
    Filed: November 18, 2011
    Publication date: January 30, 2014
    Applicant: ForSight Vision4, Inc.
    Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela MacFarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
  • Publication number: 20110171312
    Abstract: Modified therapeutic peptide compositions comprising conjugates of therapeutic peptides covalently coupled to one or more hydrophilic polymers. Optionally, the therapeutic peptide is also covalently coupled to one or more moieties having one to ten carbon atoms. Methods of making and use are also provided. The conjugates, when administered by any of a number of administration routes, exhibit characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer and/or one or moiety having one to ten carbon atoms.
    Type: Application
    Filed: September 17, 2009
    Publication date: July 14, 2011
    Applicant: Nektar Therapeutics
    Inventors: Mei-Chang Kuo, Blaine Bueche, Mary J. Bossard, Cindy L. Barnes
  • Publication number: 20060018840
    Abstract: An aerosolizable formulation comprises free-base nicotine, an organic acid, and a hydrofluoroalkane propellant. The organic acid is present in a mole ratio with said nicotine in a range of about 0.25:1 (organic acid:nicotine) to about 4:1 (organic acid:nicotine). The organic acid and said free-base nicotine form a nicotine salt. An equivalent mixture of free-base nicotine and organic acid in water has a pH between about pH 3.0 and about pH 9.0. The aerosolizable formulation is aerosolizable, for example, by a metered dose inhaler for administration to a user.
    Type: Application
    Filed: June 28, 2005
    Publication date: January 26, 2006
    Applicant: Nektar Therapeutics
    Inventors: David Lechuga-Ballesteros, Mei-Chang Kuo, Yuan Song, Blaine Bueche
  • Publication number: 20050152848
    Abstract: The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
    Type: Application
    Filed: November 2, 2004
    Publication date: July 14, 2005
    Inventors: John Patton, Mei-Chang Kuo, J. Harris, Chester Leach, Kimberly Perkins, Blaine Bueche
  • Patent number: 6890518
    Abstract: The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: May 10, 2005
    Assignee: Nektar Therapeutics
    Inventors: John S. Patton, Mei-Chang Kuo, J. Milton Harris, Chester Leach, Kimberly Perkins, Blaine Bueche
  • Patent number: 6838076
    Abstract: The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: January 4, 2005
    Assignee: Nektar Therapeutics
    Inventors: John S. Patton, Mei-Chang Kuo, J. Milton Harris, Chester Leach, Kimberly Perkins, Blaine Bueche
  • Publication number: 20030216542
    Abstract: The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
    Type: Application
    Filed: April 1, 2003
    Publication date: November 20, 2003
    Inventors: John S. Patton, Mei-Chang Kuo, J. Milton Harris, Chester Leach, Kimberly Perkins, Blaine Bueche
  • Publication number: 20030118510
    Abstract: The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
    Type: Application
    Filed: May 21, 2002
    Publication date: June 26, 2003
    Inventors: John S. Patton, Mei-Chang Kuo, J. Milton Harris, Chester Leach, Kimberly Perkins, Blaine Bueche